Yamazaki N, et al. - The safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of dabrafenib (150 mg BID) plus trametinib (2 mg QD) in Japanese patients with BRAF V600E/K mutant solid tumors (phase 1) and melanoma (phase 2) were determined. The data revealed that the plasma concentrations of dabrafenib and trametinib reached a steady state by week 3. Hence, the efficacy and PK properties of the dabrafenib+trametinib combination in Japanese patients were shown to be comparable with those noted in global studies.